CytoMed Therapeutics Limited
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CytoMed Therapeutics Limited (NASDAQ: GDTC), a clinical-stage biopharmaceutical company spun out from Singapore's Agency for Science, Technology and Research (A*STAR) in 2018 and headquartered at 1 Commonwealth Lane in Singapore, develops proprietary allogeneic off-the-shelf cell-based immunotherapies targeting a broad spectrum of solid tumors and hematological cancers. The company leverages patent-pending technologies to engineer gamma delta (γδ) T cell therapies, including its lead clinical trial-ready CAR-γδ T cell product CMT-N2D and natural killer (NK) cell therapies; induced pluripotent stem cell (iPSC)-derived cellular therapeutics; and cord blood-derived NK cells and biologics for cancers and autoimmune diseases. It operates primarily in Singapore and Malaysia, with research collaborations including Sengkang General Hospital for CTM-MSC Phase I trials and SunAct Cancer Institute for GMP-grade CTM-GDT clinical trials, while expanding therapeutic access to markets in China and India. In recent developments, CytoMed completed the acquisition of a licensed cord blood bank in Malaysia in October 2024 through its subsidiary LongevityBank to secure cost-free raw materials for cord blood-derived therapeutics; announced a cash bid in October 2025 for TC BioPharm's TCB-002 γδ T cell technology, which completed Phase I trials in Europe, followed by finalizing the acquisition in November 2025 to accelerate non-viral allogeneic platforms for cancer treatment in Asia; dosed its first patient in the Phase I ANGELICA trial of allogeneic CAR-γδ T cell therapy for advanced solid tumors and hematological malignancies, supported by NMRC funding; and plans to spin off LongevityBank as a standalone entity focused on cord blood-based biopharmaceuticals.
CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 11% – Here’s What Happened
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology